Passive immunotherapies targeting Aβ and tau in Alzheimer's disease.

ABSTRACT: Amyloid-β (Aβ) and tau proteins currently represent the two most promising targets to treat Alzheimer's disease. The most extensively developed method to treat the pathologic forms of these proteins is through the administration of exogenous antibodies, or passive immunotherapy. In this review, we discuss the molecular-level strategies that researchers are using to design an effective therapeutic antibody, given the challenges in treating this disease. These challenges include selectively targeting a protein that has misfolded or is pathological rather than the more abundant, healthy protein, designing strategic constructs for immunizing an animal to raise an antibody that has the appropriate conformational selectivity to achieve this end, and clearing the pathological protein species befo

SUBMITTER: Plotkin SS 

PROVIDER: S-EPMC7365083 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature